Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 2/20 | 0.61 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.61 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.61 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.61 |
| ▸ | HTR2B | P41595 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.61 |
| ▸ | HTR3B | O95264 | 1/20 | 0.61 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.61 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.39 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL9052012 | 0.94 | HTR3A (0.56) | HTR3AADRA2AADRA2BADRA2CSLC6A4 | |
| SCHEMBL3178647 | 0.91 | HTR3A (0.51) | HTR3AADRA2AADRA2BADRA2CSLC6A4 | |
| Fumaric Acid SCHEMBL9051124 | 0.86 | HTR3A (0.46) | HTR3AADRA2AADRA2BADRA2CSLC6A4 | |
| SCHEMBL6851382 | 0.81 | HTR3A (0.65) | HTR3AADRA2AADRA2BADRA2CSLC6A4 | |
| SCHEMBL9050458 | 0.80 | HTR3A (0.64) | HTR3AADRA2AADRA2BADRA2CSLC6A4 | |
| SCHEMBL6850907 | 0.77 | HTR3A (0.60) | HTR3AADRA2AADRA2BADRA2CSLC6A4 | |
| Ramosetron SCHEMBL9048400 | 0.76 | HTR3A (1.00) | HTR3AADRA2AADRA2BADRA2CSLC6A4 | |
| Ramosetron SCHEMBL3865249 | 0.76 | HTR3A (1.00) | HTR3AADRA2AADRA2BADRA2CSLC6A4 | |
| Ramosetron SCHEMBL1649718 | 0.76 | HTR3A (1.00) | HTR3AADRA2AADRA2BADRA2CSLC6A4 | |
| Ramosetron SCHEMBL8544326 | 0.75 | HTR3A (0.98) | HTR3AADRA2AADRA2BADRA2CSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652052-B2 | Process for producing ramosetron or its salt | ASTELLAS PHARMA INC. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-20090069570-A1 | Novel Process for Producing Ramosetron or Its Salt | ASTELLAS PHARMA INC. (JP) | 2009-03-12 | — | — | US | disclosed |
| EP-1870408-A1 | NOVEL PROCESS FOR PRODUCING RAMOSETRON OR ITS SALT | Astellas Pharma Inc. (JP) | 2007-12-26 | — | — | EP | disclosed |
| EP-0381422-B1 | Tetrahydrobenzimidazole derivatives | YAMANOUCHI PHARMA CO LTD (JP) | 1996-10-23 | — | — | EP | disclosed |
| US-5496942-A | 5-HT3-RECEPTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1996-03-05 | — | — | US | disclosed |
| US-5344927-A | 5-HT3 antagonist | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1994-09-06 | — | — | US | disclosed |
| EP-0381422-A1 | Tetrahydrobenzimidazole derivatives | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1990-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069570-A1 | Novel Process for Producing Ramosetron or Its Salt | SI, VIP, HTR1D | HTR3A 101/4885ADRA2A 317/4885ADRA2B 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.